BioXcel Therapeutics, Inc.

BioXcel Therapeutics, Inc. is a U.S.-based biopharmaceutical company that uses an AI-driven drug development approach to identify and advance new therapies in neuroscience and immuno-oncology. Its most advanced commercial product is IGALMI®, an orally dissolving sublingual film of dexmedetomidine approved for agitation associated with schizophrenia or bipolar I/II disorder in adults. The company’s pipeline is centered on BXCL501 for additional agitation-related indications, including Alzheimer’s dementia, and BXCL701, an investigational oral innate immune activator for aggressive cancers. BioXcel also relies on its relationship with BioXcel LLC and the EvolverAI platform for certain R&D and technology support, which makes its operating model unusually dependent on both internal development and shared-services arrangements.

−7 813,2 %

74,5 %

−10 887,4 %

−71,7 %

0.83

0.82

— BioXcel Therapeutics, Inc.
%
Commercial product100% IGALMI® sales for the treatment of acute agitation in approved adult psychiatric settings.
Neuroscience pipeline0% BXCL501 development for agitation associated with Alzheimer’s dementia and other CNS indications.
Immuno-oncology pipeline0% BXCL701 development for aggressive prostate cancer, pancreatic cancer, and other tumors.
AI-enabled discovery platform0% EvolverAI-based and in-house AI tools used to identify and optimize new therapeutic candidates.

The company’s current paying customers are healthcare providers and institutions that purchase IGALMI through the...

  • Institutional healthcare buyersprimary

    Hospitals, emergency departments, and care facilities purchase IGALMI through pharmaceutical distribution channels because they need a fast-acting agitation treatment in supervised settings.

  • GPOs and intermediariesprimary

    Group purchasing organizations and other intermediaries negotiate access and pricing for IGALMI, shaping market penetration and reimbursement terms.

  • Clinicians and prescriberssecondary

    Psychiatrists, neurologists, and care teams influence whether approved and future formulations are used in practice based on efficacy, safety, and ease of administration.

  • Payers and formulary committeessecondary

    Health plans and institutional formularies determine access and net realized pricing for commercial product uptake.

  • Clinical research ecosystemsecondary

    Trial sites, investigators, and CROs support the development of BXCL501 and BXCL701 by generating the data needed for regulatory approval.

BioXcel Therapeutics is headquartered in the United States and its reported revenue is generated from U.S...

  • •United States is the core market for IGALMI sales and clinical development
  • •FDA regulation is central because product approvals and label changes drive commercialization
  • •U.S. hospital and institutional channels determine access for the commercial product
  • •No meaningful country-level revenue diversification is disclosed in the excerpts
  • •Operational dependence on U.S.-based financing and capital markets is material
  • •Clinical trial execution is primarily tied to U.S. sites and regulatory processes

BioXcel’s near-term strategy is to preserve cash while prioritizing BXCL501 development and supporting IGALMI...

01
Preserve cash and extend runwayshort-term

The company has limited liquidity and substantial doubt about going concern, so cost control is necessary to keep development programs alive.

02
Advance BXCL501 in Alzheimer’s agitationmedium-term

BXCL501 is the most important pipeline asset and the main path to a larger neuroscience market opportunity.

03
Grow IGALMI market accessshort-term

IGALMI is the only commercial product and the source of product revenue needed to support operations.

04
Maintain AI-enabled development capabilitymedium-term

The company’s differentiation depends on its AI platform and access to EvolverAI for candidate identification and optimization.

BioXcel faces substantial financing and going-concern risk because it has a limited revenue base, negative operating...

critical

Liquidity shortfall and going-concern uncertainty

The company has negative working capital, ongoing operating losses, and stated dependence on additional financing to fund operations.

Scope
Corporate funding and clinical development continuity
Materiality
high
high

Clinical development failure or delay

BXCL501 and BXCL701 are still investigational, so unfavorable data or trial delays could eliminate future value creation.

Scope
Pipeline programs
Materiality
high
high

Regulatory and safety risk

FDA actions such as label restrictions, REMS, warnings, or withdrawal of approval could reduce product utility and market acceptance.

Scope
IGALMI and future approved products
Materiality
high
high

Commercial uptake risk for IGALMI

The company disclosed limited market access since launch, which constrains revenue growth and operating leverage.

Scope
Commercial product revenue
Materiality
high
medium

Related-party and technology dependency

BioXcel relies on BioXcel LLC for services and access to EvolverAI, creating operational and governance dependence.

Scope
R&D support and technology platform
Materiality
medium
medium

Intellectual property and patent risk

The value of the pipeline depends on patent protection and successful prosecution of new applications.

Scope
BXCL501, BXCL701, platform technologies
Materiality
medium
Net product revenue estimation
Revenue and gross margin
Clinical trial and R&D cost accruals
Operating loss and cash flow comparability
Derivative fair value accounting
Other income/expense
Restructuring and severance accruals
Operating expenses and liabilities

Annexon, Inc.

ANNX · Pharmaceutical Preparations

BIOVIE INC.

BIVI · Pharmaceutical Preparations

BIOGEN INC.

BIIB · Biological Products, (No Diagnostic Substances)

Axsome Therapeutics, Inc.

AXSM · Pharmaceutical Preparations

Atai Beckley N.V.

ATAI · Pharmaceutical Preparations

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

: 11/08/2026